A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study.

Drug Des Devel Ther · 2019 · PMC6352870 · PMID 30774311

Europe PMC DOI

hedged sentence

0.0840

closest p · 1.7× alpha

0.0840

boldest claim

The sentences

marginally significantP =0.084so close (0.05 < p ≤ 0.1)

A significant increase of total bilirubin (+1.97 mg/dL [+0.77; +3.44]; P =0.004) and a marginally significant decline in eGFR (−9.5 mL/min/1.73 m 2 [−16; −2]; P =0.084) were observed during the treatment with DTG plus ATV/r.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.